Search Medical Condition
Please enter condition
Please choose location

Parow, South Africa Clinical Trials

A listing of Parow, South Africa clinical trials actively recruiting patients volunteers.

RESULTS

Found (89) clinical trials

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

0.0 miles

Learn More »

This clinical trial is provided by Antidote. If successful this drug will reduce the risk of end stage kidney disease in patients with Type 2 diabetes mellitus

Phase

0.67 miles

Learn More »

This clinical trial is provided by Antidote. If approved the drug may be successful in preventing first time major cardiovascular events ( such as heart attacks, strokes) in type 2 diabetic patients who are at high risk of experiencing a major cardiovascular event.

Phase

0.67 miles

Learn More »

This clinical trial is provided by Antidote. If successful the study drug will show superior lowering of LDL cholesterol levels in subjects with HeFH and at high and very high risk of cardiovascular events recieving maximally tolerated dose of statin therapy

Phase

0.67 miles

Learn More »

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

This is a randomized, observer-blind, placebo-controlled group-sequential design trial enrolling third-trimester pregnant women in the Northern and Southern hemispheres, for up to four consecutive RSV seasons in each hemisphere. The trial is projected to enroll an estimated maximum of 8,618 third-trimester pregnant subjects, but numbers may be smaller based on ...

Phase

1.24 miles

Learn More »

A Phase 3 Randomized Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

The study seeks to evaluate the efficacy and tolerability of veliparib/placebo in combination with carboplatin and paclitaxel in HER2-negative metastatic or locally advanced, unresectable, BRCA-associated breast cancer.

Phase

1.54 miles

Learn More »

A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) prolongs progression free survival (PFS) and overall survival (OS) in participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor (EGFR) amplification. In addition, there is a Phase 1, open-label, multicenter sub-study to ...

Phase

1.67 miles

Learn More »

Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection

This study will evaluate the safety and PKs of RAL given to HIV-1-exposed newborn infants at risk of acquiring HIV-1 infection. The study also seeks to determine the appropriate dosing regimen of RAL that can be safely given to infants in the first 6 weeks of life. The study will ...

Phase

1.82 miles

Learn More »

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Pregnant women experience unique physiological changes that may result in clinically significant alterations in drug PKs. Unfortunately, there have been few clinical trials to study the PKs of ARV, TB, and hormonal contraceptive drugs in pregnant women. The development of appropriate dosing regimens for the HIV-infected pregnant woman is critical ...

Phase

1.83 miles

Learn More »

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The trial is an open label extension study. Eligible patients from the RPC01-3101 trial diagnosed with moderate to severe ulcerative colitis will be enrolled to receive study medication for up to 5 years or until marketed approval.

Phase

1.84 miles

Learn More »